(Source: Optimi Health)
  • Optimi Health (CSE:OPTI) recently touted several milestones it had achieved in its international psychedelic supply operations strategy
  • The microcap psychedelics manufacturer completed its first international shipment to Israel of its MDMA active pharmaceutical ingredient to Tel Aviv University
  • This was thanks to an export permit granted from Health Canada to help facilitate Optimi’s work to support global psychedelic research and innovation
  • Optimi Health Corp. stock opened trading at 0.375 per share

Optimi Health (CSE:OPTI) recently touted several milestones it had achieved in its international psychedelic supply operations strategy.

The microcap psychedelics manufacturer announced it had completed its first international shipment to Israel of its in-house manufactured MDMA active pharmaceutical ingredient to the Institute for Psychedelic Research at Tel Aviv University.

This was thanks to an export permit granted from Health Canada to help facilitate Optimi’s work to support global psychedelic research and innovation.

“Completing our first International export of MDMA to Israel is an important milestone for the company,” Optimi’s CEO, Bill Ciprick said in a news release. “Now that we have our Drug Establishment Licence, this accomplishment highlights our capability to manufacture MDMA in-house for clients around the world, and efficiently deliver the product to an international client. It also underscores our dedication to expanding the availability of high-quality, controlled substances for important scientific research and therapeutic applications worldwide.”

By obtaining the Canadian Export Reporting System and Canada Border Services Agency exporter authorization I.D., the Vancouver-based company has affirmed its ability to export controlled substances from Canada. This authorization is essential for adhering to international trade regulations and facilitating seamless logistics for future global shipments.

The company also highlighted its drug establishment licence secured from Health Canada earlier this month. It allows the team to produce and distribute its MDMA and psilocybin capsules, and to fabricate active pharmaceutical ingredients extracted from plant sources. Optimi is now recognized by Health Canada as a GMP-compliant pharmaceutical drug manufacturer.

Optimi Health is a Health Canada-licensed psychedelics pharmaceutical manufacturer focused on controlled substances such as botanical psilocybin and MDMA and functional mushrooms that focus on the health and wellness markets.

Optimi Health Corp. stock (CSE:OPTI) opened trading at 0.375 per share. The stock has added 65.22 per cent year-over-year, but remains down 59.57 per cent since inception in 2021.

Join the discussion: Learn what other investors are saying about this psychedelic stock on the Optimi Health Corp. Bullboard, and check out Stockhouse’s stock forums and message boards.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.

(Top image: Optimi Health)


More From The Market Online

The Market Online’s Weekly Cannabis Report – June 14, 2024

A top Mexican cannabis and CBD company revealed it has executed the first purchase order of products from Restorative Botanicals in the U.S.

Bragg Gaming continues global expansion, teams with Kingsbet

Bragg Gaming Group (TSX:BRAG) launches its full turnkey solution with Czech land-based casino operator Kings Entertainment A.S.

Musk earns shareholder support at Tesla’s annual meeting

At Thursday's annual shareholder meeting, Tesla (NDAQ:TSLA) investors voted in favour of CEO Elon Musk's US$55.8 billion pay package.